Qianyu Shen , Dennis Chin Wee Chua , Po Fun Chan , Hwee Lin Wee
{"title":"在新加坡开发包含心力衰竭用药成本信息的决策辅助工具","authors":"Qianyu Shen , Dennis Chin Wee Chua , Po Fun Chan , Hwee Lin Wee","doi":"10.1016/j.pecinn.2024.100342","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>This study presents the development process of a heart failure (HF) medication decision aid (DA) specific to Singapore context, with the objective of promoting cost conversations.</p></div><div><h3>Methods</h3><p>Phase 1 was to create a DA prototype, where two HF clinicians were consulted on their input and needs. Phase 2 was pilot testing where the prototype was tested on HF patients and revised based on their feedback.</p></div><div><h3>Results</h3><p>The DA is a one-page poster that compares only two classes of HF medications. It encompasses seven attributes for comparison, including route of administration, treatment duration, frequency of use, hospitalization rate, survival rate, low blood pressure probability with personalized subsidized cost being the key attribute. A total of 48 patients participated in the pilot testing with only 2 patients (4.2 %) finding the DA difficult to understand. Almost all patients agreed that the DA provided greater clarity in the medication options.</p></div><div><h3>Conclusion</h3><p>By integrating the needs of both clinicians and patients and conducting user testing, we developed a novel HF medication DA. Patients found the tool easy to understand and acceptable.</p></div><div><h3>Innovation</h3><p>This innovative DA aims to improve cost conversations by providing tailored, concise, and locally relevant information for efficient use.</p></div>","PeriodicalId":74407,"journal":{"name":"PEC innovation","volume":"5 ","pages":"Article 100342"},"PeriodicalIF":0.0000,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772628224000906/pdfft?md5=a9b719afd88e89238b9a35ebc233cb38&pid=1-s2.0-S2772628224000906-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Development of a decision aid with cost information for heart failure medication in Singapore\",\"authors\":\"Qianyu Shen , Dennis Chin Wee Chua , Po Fun Chan , Hwee Lin Wee\",\"doi\":\"10.1016/j.pecinn.2024.100342\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objective</h3><p>This study presents the development process of a heart failure (HF) medication decision aid (DA) specific to Singapore context, with the objective of promoting cost conversations.</p></div><div><h3>Methods</h3><p>Phase 1 was to create a DA prototype, where two HF clinicians were consulted on their input and needs. Phase 2 was pilot testing where the prototype was tested on HF patients and revised based on their feedback.</p></div><div><h3>Results</h3><p>The DA is a one-page poster that compares only two classes of HF medications. It encompasses seven attributes for comparison, including route of administration, treatment duration, frequency of use, hospitalization rate, survival rate, low blood pressure probability with personalized subsidized cost being the key attribute. A total of 48 patients participated in the pilot testing with only 2 patients (4.2 %) finding the DA difficult to understand. Almost all patients agreed that the DA provided greater clarity in the medication options.</p></div><div><h3>Conclusion</h3><p>By integrating the needs of both clinicians and patients and conducting user testing, we developed a novel HF medication DA. Patients found the tool easy to understand and acceptable.</p></div><div><h3>Innovation</h3><p>This innovative DA aims to improve cost conversations by providing tailored, concise, and locally relevant information for efficient use.</p></div>\",\"PeriodicalId\":74407,\"journal\":{\"name\":\"PEC innovation\",\"volume\":\"5 \",\"pages\":\"Article 100342\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-09-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2772628224000906/pdfft?md5=a9b719afd88e89238b9a35ebc233cb38&pid=1-s2.0-S2772628224000906-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"PEC innovation\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2772628224000906\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"PEC innovation","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2772628224000906","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
本研究介绍了针对新加坡国情的心力衰竭(HF)用药决策辅助工具(DA)的开发过程,目的是促进成本对话。方法第一阶段是创建一个DA原型,咨询两位HF临床医生的意见和需求。第 2 阶段是试点测试,在高血压患者身上测试原型,并根据他们的反馈意见进行修改。结果DA 是一张单页海报,仅对两类高血压药物进行比较。它包含七个比较属性,包括给药途径、疗程、使用频率、住院率、存活率、低血压概率,其中个性化补贴费用是关键属性。共有 48 名患者参与了试点测试,仅有 2 名患者(4.2%)认为 DA 难以理解。通过综合考虑临床医生和患者的需求并进行用户测试,我们开发出了一种新型的高血压药物DA。患者认为该工具易于理解和接受。创新这一创新型 DA 旨在通过提供量身定制、简明扼要且与当地相关的信息,提高使用效率,从而改善成本对话。
Development of a decision aid with cost information for heart failure medication in Singapore
Objective
This study presents the development process of a heart failure (HF) medication decision aid (DA) specific to Singapore context, with the objective of promoting cost conversations.
Methods
Phase 1 was to create a DA prototype, where two HF clinicians were consulted on their input and needs. Phase 2 was pilot testing where the prototype was tested on HF patients and revised based on their feedback.
Results
The DA is a one-page poster that compares only two classes of HF medications. It encompasses seven attributes for comparison, including route of administration, treatment duration, frequency of use, hospitalization rate, survival rate, low blood pressure probability with personalized subsidized cost being the key attribute. A total of 48 patients participated in the pilot testing with only 2 patients (4.2 %) finding the DA difficult to understand. Almost all patients agreed that the DA provided greater clarity in the medication options.
Conclusion
By integrating the needs of both clinicians and patients and conducting user testing, we developed a novel HF medication DA. Patients found the tool easy to understand and acceptable.
Innovation
This innovative DA aims to improve cost conversations by providing tailored, concise, and locally relevant information for efficient use.